Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novonco Therapeutics
Los Angeles, California, United States
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Novonco Therapeutics is developing three platform technologies based on novel small molecules for hard-to-treat cancers, including COH29 (RR and DNA repair inhibitor) licensed from City of Hope, with plans to advance to clinical trials. Preclinical data shows antitumor activity in ovarian cancer, leukemia, breast cancer, hepatocellular carcinoma, and acute myeloid leukemia.[1][4][9]
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
City of HopeUniversity of California, Irvine
Beyond the preview
Go deeper on Novonco Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novonco Therapeutics.